I agree the is no overarching conspiracy at the FD
Post# of 145825
"And during my time as a consultant, I worked with nearly all of the top 40 large cap and mid cap biopharmaceutical developers. I've seen the drug development process from end to end. And I have had the opportunity to look at over 1,000 clinical development programs across hundreds of different molecules. And, importantly, I have had the benefit of time, to see how these programs have actually played out, either in the clinic or in the markets. I have looked at these molecules through the lens of an investor, developer, a competitor or in some cases as an acquirer. Through these experiences, I've learned extensively about what the hall marks are for a clinical phase therapeutic to get to market."
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)